Pharm-Sintez

Executive Summary

Pharm-Sintez is a Russian pharmaceutical company specializing in the development and manufacture of generic prescription drugs and active pharmaceutical ingredients (APIs). Founded in 2005 and headquartered in Moscow, the company operates a fully integrated production cycle from API synthesis to finished drug manufacturing, primarily serving the subsidized medicines segment in Russia. With a focus on affordable generics, Pharm-Sintez benefits from the Russian government's import substitution policies and growing domestic demand for essential medicines. However, the company faces significant geopolitical and regulatory risks associated with operating in Russia, including Western sanctions that may restrict access to certain technologies and export markets. Despite these challenges, Pharm-Sintez has established a stable position in the domestic market, supported by long-term procurement contracts and a portfolio of critical drugs. Looking ahead, Pharm-Sintez is expected to continue capitalizing on the Russian government's priority to strengthen pharmaceutical self-sufficiency. The company's growth prospects are tied to successful product launches, expansion of its API capabilities, and potential inclusion in state-funded healthcare programs. While export opportunities are limited by sanctions, the domestic market offers a resilient demand base. Key risks include currency fluctuations, regulatory changes, and potential disruptions to raw material imports. Overall, Pharm-Sintez presents a moderate investment opportunity with a conviction score of 65, reflecting stable domestic fundamentals offset by high geopolitical uncertainty.

Upcoming Catalysts (preview)

• Q3 2026Launch of New Generic Drugs under Import Substitution Program75% success
• Q4 2026Winning Tenders for Subsidized Medicines in Russia80% success
• TBDExpansion of API Production Capacity65% success